FGFR1 and breast cancer: Fibroblast growth factor receptor-1 (FGFR1), recently identified as a putative driver of endocrine resistance in breast cancer [36], is at the edges of the 8p11.2 amplicon that we found associated with early relapse in ER+ breast cancer treated with tamoxifen.